From: Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Factors | Unresolved issues | Comments |
---|---|---|
Patient factors | Non-adherence and/or non-compliance | Patient education and better understanding of disease and therapy |
Cost of therapy/visits | Individual healthcare jurisdiction cost and reimbursement policies | |
High individual treatment burden | Need for more durable agents | |
Poor prognosis | Need for more efficacious agents or regenerative therapies to reverse damage by nAMD | |
Therapeutic factors | Relatively short duration of action resulting in repeated treatments | Need for more durable agents |
Poor efficacy resulting in persistently active disease | Need for more efficacious agents | |
Safety profile | Need for better preclinical safety models that can provide early safety signals before entry into clinical practice | |
Healthcare system factors | High treatment burden to society | Combination of more durable and efficacious agents may help address this unmet need by preventing/reversing blindness from nAMD |
Reimbursement and subsidies | Individual healthcare jurisdiction cost and reimbursement policies | |
Increasing patient load | Need for more durable agents and/or more precise therapies to minimise unnecessary monitoring visits |